Daneng Li
Overview
Explore the profile of Daneng Li including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
99
Citations
5010
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Finn R, Ryoo B, Hsu C, Li D, Burgoyne A, Cotter C, et al.
Lancet Oncol
. 2025 Jan;
26(2):214-226.
PMID: 39855251
Background: PD-L1 and VEGF blockade with atezolizumab plus bevacizumab has been shown to improve survival in unresectable hepatocellular carcinoma. TIGIT is an immune checkpoint regulator implicated in many cancers, including...
2.
Finn R, Galle P, Ducreux M, Cheng A, Reilly N, Nicholas A, et al.
Liver Cancer
. 2024 Dec;
13(6):655-668.
PMID: 39687036
Introduction: Atezolizumab plus bevacizumab significantly improved overall survival (OS) and progression-free survival (PFS) versus sorafenib in patients with unresectable hepatocellular carcinoma (HCC) in IMbrave150. Efficacy and safety in patient subpopulations...
3.
Bahri N, Crook C, Li D, Daneng Li Md
Oncology (Williston Park)
. 2024 Nov;
38(11):442-443.
PMID: 39570708
The incidence of neuroendocrine tumors (NETs) in the US is rising, with 8.3 cases per 100,000 individuals diagnosed in 2018 compared with 6.98 cases per 100,000 individuals diagnosed in 2012....
4.
Macarulla T, Ren Z, Chon H, Park J, Kim J, Pressiani T, et al.
J Clin Oncol
. 2024 Oct;
43(5):545-557.
PMID: 39423355
Purpose: Biliary tract cancers (BTCs) harbor an immunosuppressed tumor microenvironment and respond poorly to PD-1/PD-L1 inhibitors. Bevacizumab (anti-vascular endothelial growth factor) plus chemotherapy can promote anticancer immunity, augmenting response to...
5.
Mahuron K, Limbach K, Hernandez M, Ituarte P, Li D, Kessler J, et al.
J Clin Med
. 2024 Sep;
13(17).
PMID: 39274193
: Although survival outcomes for neuroendocrine liver metastases (NETLM) are improved with liver-direct therapies (LDT), including hepatic debulking and nonsurgical trans-arterial embolization, the benefit is less established in the setting...
6.
Cabrera Chien L, Sun C, Kim H, Uranga C, Soto-Perez-de-Celis E, Burhenn P, et al.
J Geriatr Oncol
. 2024 Sep;
16(1):102063.
PMID: 39271412
No abstract available.
7.
Li D, Crook C, Chung V, Brar G, Fakih M, Barzi A, et al.
Future Oncol
. 2024 Sep;
20(33):2521-2531.
PMID: 39263892
Biliary tract cancers are a rare diagnosis with a rising incidence. Up to 20% of patients have peritoneal metastases, resulting in symptoms of ascites, abdominal pain and potential bowel obstruction....
8.
Jayani R, Hamparsumian A, Sun C, Li D, Cabrera Chien L, Moreno J, et al.
Cancer
. 2024 Aug;
130(22):3894-3901.
PMID: 39097801
Background: Depression and anxiety are prevalent in older adults with cancer but are often undertreated. Older adults are also at increased risk of chemotherapy toxicity (CT). This study evaluated the...
9.
Li D, Cheng S, Wilson Woods A, Luong A, Schiltz S, Tan R, et al.
J Hepatocell Carcinoma
. 2024 Jul;
11:1439-1444.
PMID: 39050811
Asian Americans and Pacific Islanders have an increased risk of developing liver cancer and higher risk of death compared to non-Hispanic White individuals. The role of individual-level risk factors, social...
10.
Badhrinarayanan S, Cotter C, Zhu H, Lin Y, Kudo M, Li D
Future Oncol
. 2024 Jun;
20(28):2049-2057.
PMID: 38861301
Atezolizumab plus bevacizumab is a standard of care, first-line therapy for advanced hepatocellular carcinoma (HCC). Myeloid and T regulatory cells are key immunosuppressive cell types within the hepatic tumor microenvironment...